Display options
Cite
Espinola-Zavaleta N, Vega A, Basto DM, et al. Survival and clinical behavior of hypertrophic cardiomyopathy in a latin american cohort in contrast to cohorts from the developed world. J Cardiovasc Ultrasound. 2015;23(1):20-6doi: 10.4250/jcu.2015.23.1.20.
Espinola-Zavaleta, N., Vega, A., Basto, D. M., Alcantar-Fernández, A. C., Guarner Lans, V., & Soto, M. E. (2015). Survival and clinical behavior of hypertrophic cardiomyopathy in a latin american cohort in contrast to cohorts from the developed world. Journal of cardiovascular ultrasound, 23(1), 20-6. https://doi.org/10.4250/jcu.2015.23.1.20
Espinola-Zavaleta, Nilda, et al. "Survival and clinical behavior of hypertrophic cardiomyopathy in a latin american cohort in contrast to cohorts from the developed world." Journal of cardiovascular ultrasound vol. 23,1 (2015): 20-6. doi: https://doi.org/10.4250/jcu.2015.23.1.20
Espinola-Zavaleta N, Vega A, Basto DM, Alcantar-Fernández AC, Guarner Lans V, Soto ME. Survival and clinical behavior of hypertrophic cardiomyopathy in a latin american cohort in contrast to cohorts from the developed world. J Cardiovasc Ultrasound. 2015 Mar;23(1):20-6. doi: 10.4250/jcu.2015.23.1.20. Epub 2015 Mar 30. PMID: 25883752; PMCID: PMC4398780.
Copy Download .nbib Format: NLM
Share it on

J Cardiovasc Ultrasound. 2015 Mar;23(1):20-6. doi: 10.4250/jcu.2015.23.1.20. Epub 2015 Mar 30.

Survival and clinical behavior of hypertrophic cardiomyopathy in a latin american cohort in contrast to cohorts from the developed world.

Journal of cardiovascular ultrasound

Nilda Espinola-Zavaleta, Antonio Vega, Diego Martínez Basto, Ana Cecilia Alcantar-Fernández, Veronica Guarner Lans, María Elena Soto

Affiliations

  1. Echocardiographic Outpatient Department, National Institute of Cardiology Ignacio Chavez, Mexico City, Mexico.
  2. Cardiology Department, National Institute of Cardiology Ignacio Chavez, Mexico City, Mexico.
  3. Coahuila University, Mexico City, Mexico.
  4. Physiology Department, National Institute of Cardiology Ignacio Chavez, Mexico City, Mexico.
  5. Immunology Department, National Institute of Cardiology Ignacio Chavez, Mexico City, Mexico.

PMID: 25883752 PMCID: PMC4398780 DOI: 10.4250/jcu.2015.23.1.20

Abstract

BACKGROUND: Hypertrophic cardiomyopathy (HCM) is the most common hereditary heart disease with diverse phenotipyc, genetic expession and clinical presentations. The evolution of patients with HCM in Latin America has not been properly described being the frequency, the long-term prognosis as well as the predominant phenotypic expression still unknown. The aim of this study was to determine the survival rate of HCM patients having different phenotypes in a Mexican cohort of patients.

METHODS: Clinical and echocardiographic data obtained from 77 Mexican patients with recently diagnosed HCM were analyzed. The follow-up was of 12.5 years.

RESULTS: 96.1% of patients were in functional class I/II according to the New York Heart Association, 2.6% in class III and 1.3% in class IV. Only 3.9% of them went to surgery for myectomy. During the follow-up, 17 patients (22%) died: 4/9 (44%) had apical HCM, 5/20 (25%) had obstructive septal asymmetric HCM, 6/35 (17%) had nonobstructive septal asymmetric HCM and 2/3 (15%) had concentric HCM. The survival rate was worse for patients with apical HCM, followed by those with obstructive and nonobstructive septal asymmetric HCM and patients showing concentric HCM had the best survival rates. There is significant difference in survival rates which declined in 65% in a 9 years-period. Log rank test showed significant differences (p < 0.002).

CONCLUSION: The survival rate of patients with HCM was worse in those with apical variety. The majority of patients received medical treatment. The indication for myectomy was below that observed in other international centers.

Keywords: Apical hypertrophic cardiomyopathy; Latinamerican cohort; Myectomy

References

  1. Eur Heart J. 2006 Aug;27(16):1933-41 - PubMed
  2. Ann Thorac Surg. 2008 May;85(5):1527-35, 1535.e1-2 - PubMed
  3. Circ Res. 1998 Sep 21;83(6):580-93 - PubMed
  4. Eur Heart J. 2014 Aug 7;35(30):2010-20 - PubMed
  5. Am J Med. 2004 Jan 1;116(1):63-5 - PubMed
  6. Am J Cardiol. 1981 Mar;47(3):532-8 - PubMed
  7. J Am Soc Echocardiogr. 2011 Jul;24(7):775-81 - PubMed
  8. Rev Esp Cardiol. 2000 Jan;53(1):123-30 - PubMed
  9. Circulation. 2003 Jul 29;108(4):395-8 - PubMed
  10. N Engl J Med. 2003 Jan 23;348(4):295-303 - PubMed
  11. Circulation. 2002 Sep 10;106(11):1312-6 - PubMed
  12. Circulation. 1995 Aug 15;92 (4):785-9 - PubMed
  13. J Am Coll Cardiol. 2002 Feb 20;39(4):638-45 - PubMed
  14. Am J Cardiol. 2013 Jun 15;111(12 ):1784-91 - PubMed
  15. Circulation. 2005 Nov 1;112(18):2805-11 - PubMed
  16. J Am Coll Cardiol. 2000 Dec;36(7):2212-8 - PubMed
  17. Am J Cardiol. 1981 Sep;48(3):418-28 - PubMed
  18. Heart. 2003 Oct;89(10):1179-85 - PubMed
  19. Circulation. 1995 Oct 1;92(7):1680-92 - PubMed
  20. Curr Probl Cardiol. 2004 May;29(5):239-91 - PubMed
  21. J Am Coll Cardiol. 2011 Dec 13;58(25):e212-60 - PubMed
  22. Nat Genet. 1997 Aug;16(4):379-82 - PubMed
  23. J Mol Diagn. 2009 Jan;11(1):12-6 - PubMed
  24. Cell. 1990 Sep 7;62(5):999-1006 - PubMed
  25. Exp Clin Cardiol. 2013 Winter;18(1):e47-9 - PubMed

Publication Types